Cargando…
Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New ’Hit Hard First and then Maintain’ Regimen of Administration
(1) Background: The aim of the present pilot study was to study the effect of a new oral gonadotropin-releasing hormone antagonist on adenomyosis. (2) Methods: Eight premenopausal women, aged between 37 and 45 years, presenting with heavy menstrual bleeding, pelvic pain, and dysmenorrhea due to diff...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706704/ https://www.ncbi.nlm.nih.gov/pubmed/34945090 http://dx.doi.org/10.3390/jcm10245794 |
_version_ | 1784622257912414208 |
---|---|
author | Donnez, Jacques Donnez, Olivier Tourniaire, Jean Brethous, Michel Bestel, Elke Garner, Elizabeth Charpentier, Sébastien Humberstone, Andrew Loumaye, Ernest |
author_facet | Donnez, Jacques Donnez, Olivier Tourniaire, Jean Brethous, Michel Bestel, Elke Garner, Elizabeth Charpentier, Sébastien Humberstone, Andrew Loumaye, Ernest |
author_sort | Donnez, Jacques |
collection | PubMed |
description | (1) Background: The aim of the present pilot study was to study the effect of a new oral gonadotropin-releasing hormone antagonist on adenomyosis. (2) Methods: Eight premenopausal women, aged between 37 and 45 years, presenting with heavy menstrual bleeding, pelvic pain, and dysmenorrhea due to diffuse and disseminated uterine adenomyosis, confirmed by magnetic resonance imaging (MRI), received 200 mg linzagolix once daily for a period of 12 weeks, after which they were switched to 100 mg linzagolix once daily for another 12 weeks. The primary efficacy endpoint was the change in volume of the adenomyotic uterus from baseline to 24 weeks, evaluated by MRI. Secondary efficacy endpoints included the change in uterine volume from baseline to 12 and 36 weeks by MRI, and also weeks 12, 24, and 36 assessed by transvaginal ultrasound (TVUS). Other endpoints were overall pelvic pain, dysmenorrhea, non-menstrual pelvic pain, dyspareunia, amenorrhea, quality of life measures, bone mineral density (BMD), junctional zone thickness, and serum estradiol values. (3) Results: Median serum estradiol was suppressed below 20 pg/mL during the 12 weeks on linzagolix 200 mg, and maintained below 60 pg/mL during the second 12 weeks on linzagolix 100 mg. At baseline, the mean ± SD uterine volume was 333 ± 250 cm(3). After 24 weeks of treatment, it was 204 ± 126 cm(3), a reduction of 32% (p = 0.0057). After 12 weeks, the mean uterine volume was 159 ± 95 cm(3), a reduction of 55% from baseline (p = 0.0001). A similar pattern was observed when uterine volume was assessed by TVUS. Improvements in overall pelvic pain, dysmenorrhea, non-menstrual pelvic pain, dyspareunia, and dyschezia, as well as quality of life measured using the EHP-30 were also observed. Mean percentage BMD loss at 24 weeks was, respectively, −2.4%, −1.3%, and −4.1% for the spine, femoral neck, and total hip. The most common adverse events were hot flushes, which occurred in 6/8 women during the first 12 weeks, and 1/8 women between 12 and 24 weeks. (4) Conclusions: Linzagolix at a dose of 200 mg/day reduced uterine volume, and improved clinically relevant symptoms. Treatment with 100 mg thereafter retains the therapeutic benefits of the starting dose while minimizing side effects. This ‘hit hard first and then maintain’ approach may be the optimal way to treat women with symptomatic adenomyosis. |
format | Online Article Text |
id | pubmed-8706704 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87067042021-12-25 Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New ’Hit Hard First and then Maintain’ Regimen of Administration Donnez, Jacques Donnez, Olivier Tourniaire, Jean Brethous, Michel Bestel, Elke Garner, Elizabeth Charpentier, Sébastien Humberstone, Andrew Loumaye, Ernest J Clin Med Article (1) Background: The aim of the present pilot study was to study the effect of a new oral gonadotropin-releasing hormone antagonist on adenomyosis. (2) Methods: Eight premenopausal women, aged between 37 and 45 years, presenting with heavy menstrual bleeding, pelvic pain, and dysmenorrhea due to diffuse and disseminated uterine adenomyosis, confirmed by magnetic resonance imaging (MRI), received 200 mg linzagolix once daily for a period of 12 weeks, after which they were switched to 100 mg linzagolix once daily for another 12 weeks. The primary efficacy endpoint was the change in volume of the adenomyotic uterus from baseline to 24 weeks, evaluated by MRI. Secondary efficacy endpoints included the change in uterine volume from baseline to 12 and 36 weeks by MRI, and also weeks 12, 24, and 36 assessed by transvaginal ultrasound (TVUS). Other endpoints were overall pelvic pain, dysmenorrhea, non-menstrual pelvic pain, dyspareunia, amenorrhea, quality of life measures, bone mineral density (BMD), junctional zone thickness, and serum estradiol values. (3) Results: Median serum estradiol was suppressed below 20 pg/mL during the 12 weeks on linzagolix 200 mg, and maintained below 60 pg/mL during the second 12 weeks on linzagolix 100 mg. At baseline, the mean ± SD uterine volume was 333 ± 250 cm(3). After 24 weeks of treatment, it was 204 ± 126 cm(3), a reduction of 32% (p = 0.0057). After 12 weeks, the mean uterine volume was 159 ± 95 cm(3), a reduction of 55% from baseline (p = 0.0001). A similar pattern was observed when uterine volume was assessed by TVUS. Improvements in overall pelvic pain, dysmenorrhea, non-menstrual pelvic pain, dyspareunia, and dyschezia, as well as quality of life measured using the EHP-30 were also observed. Mean percentage BMD loss at 24 weeks was, respectively, −2.4%, −1.3%, and −4.1% for the spine, femoral neck, and total hip. The most common adverse events were hot flushes, which occurred in 6/8 women during the first 12 weeks, and 1/8 women between 12 and 24 weeks. (4) Conclusions: Linzagolix at a dose of 200 mg/day reduced uterine volume, and improved clinically relevant symptoms. Treatment with 100 mg thereafter retains the therapeutic benefits of the starting dose while minimizing side effects. This ‘hit hard first and then maintain’ approach may be the optimal way to treat women with symptomatic adenomyosis. MDPI 2021-12-10 /pmc/articles/PMC8706704/ /pubmed/34945090 http://dx.doi.org/10.3390/jcm10245794 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Donnez, Jacques Donnez, Olivier Tourniaire, Jean Brethous, Michel Bestel, Elke Garner, Elizabeth Charpentier, Sébastien Humberstone, Andrew Loumaye, Ernest Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New ’Hit Hard First and then Maintain’ Regimen of Administration |
title | Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New ’Hit Hard First and then Maintain’ Regimen of Administration |
title_full | Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New ’Hit Hard First and then Maintain’ Regimen of Administration |
title_fullStr | Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New ’Hit Hard First and then Maintain’ Regimen of Administration |
title_full_unstemmed | Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New ’Hit Hard First and then Maintain’ Regimen of Administration |
title_short | Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New ’Hit Hard First and then Maintain’ Regimen of Administration |
title_sort | uterine adenomyosis treated by linzagolix, an oral gonadotropin-releasing hormone receptor antagonist: a pilot study with a new ’hit hard first and then maintain’ regimen of administration |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706704/ https://www.ncbi.nlm.nih.gov/pubmed/34945090 http://dx.doi.org/10.3390/jcm10245794 |
work_keys_str_mv | AT donnezjacques uterineadenomyosistreatedbylinzagolixanoralgonadotropinreleasinghormonereceptorantagonistapilotstudywithanewhithardfirstandthenmaintainregimenofadministration AT donnezolivier uterineadenomyosistreatedbylinzagolixanoralgonadotropinreleasinghormonereceptorantagonistapilotstudywithanewhithardfirstandthenmaintainregimenofadministration AT tourniairejean uterineadenomyosistreatedbylinzagolixanoralgonadotropinreleasinghormonereceptorantagonistapilotstudywithanewhithardfirstandthenmaintainregimenofadministration AT brethousmichel uterineadenomyosistreatedbylinzagolixanoralgonadotropinreleasinghormonereceptorantagonistapilotstudywithanewhithardfirstandthenmaintainregimenofadministration AT bestelelke uterineadenomyosistreatedbylinzagolixanoralgonadotropinreleasinghormonereceptorantagonistapilotstudywithanewhithardfirstandthenmaintainregimenofadministration AT garnerelizabeth uterineadenomyosistreatedbylinzagolixanoralgonadotropinreleasinghormonereceptorantagonistapilotstudywithanewhithardfirstandthenmaintainregimenofadministration AT charpentiersebastien uterineadenomyosistreatedbylinzagolixanoralgonadotropinreleasinghormonereceptorantagonistapilotstudywithanewhithardfirstandthenmaintainregimenofadministration AT humberstoneandrew uterineadenomyosistreatedbylinzagolixanoralgonadotropinreleasinghormonereceptorantagonistapilotstudywithanewhithardfirstandthenmaintainregimenofadministration AT loumayeernest uterineadenomyosistreatedbylinzagolixanoralgonadotropinreleasinghormonereceptorantagonistapilotstudywithanewhithardfirstandthenmaintainregimenofadministration |